Free Trial

Outlook Therapeutics Q2 2023 Earnings Report

Outlook Therapeutics logo
$2.23 +0.04 (+1.83%)
As of 01/17/2025 04:00 PM Eastern

Outlook Therapeutics EPS Results

Actual EPS
-$0.60
Consensus EPS
-$1.20
Beat/Miss
Beat by +$0.60
One Year Ago EPS
N/A

Outlook Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Outlook Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A

Outlook Therapeutics Earnings Headlines

Outlook Therapeutics' (OTLK) Buy Rating Reiterated at Guggenheim
Outperform BTC without owning any crypto?
I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free…
See More Outlook Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Outlook Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Outlook Therapeutics and other key companies, straight to your email.

About Outlook Therapeutics

Outlook Therapeutics (NASDAQ:OTLK), operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

View Outlook Therapeutics Profile

More Earnings Resources from MarketBeat